Diabetes Research and Clinical Practice
Volume 82 , Pages S127-S134 , 15 December 2008

Fatty acid binding proteins in adipose tissue: A promising link between metabolic syndrome and atherosclerosis?

References 

  1. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab. 2004;89:2595–2600
  2. Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu. Rev. Med. 2005;56:45–62
  3. Ferroni P, Basili S, Falco A, Davi G. Inflammation, insulin resistance, and obesity. Curr. Atheroscler. Rep. 2004;6:424–431
  4. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J. Allergy Clin. Immunol. 2005;115:911–919(quiz 920)
  5. Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance. Nat. Clin. Pract. Endocrinol. Metab. 2006;2:335–348
  6. Makowski L, Hotamisligil GS. Fatty acid binding proteins—the evolutionary crossroads of inflammatory and metabolic responses. J. Nutr. 2004;134:2464S–2468S
  7. Makowski L, Hotamisligil GS. The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. Curr. Opin. Lipidol. 2005;16:543–548
  8. Zimmerman AW, Veerkamp JH. New insights into the structure and function of fatty acid-binding proteins. Cell. Mol. Life Sci. 2002;59:1096–1116
  9. Coe NR, Bernlohr DA. Physiological properties and functions of intracellular fatty acid-binding proteins. Biochim. Biophys. Acta. 1998;1391:287–306
  10. Chmurzynska A. The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. J. Appl. Genet. 2006;47:39–48
  11. Tan NS, Shaw NS, Vinckenbosch N, Liu P, Yasmin R, Desvergne B, et al. Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol. Cell. Biol. 2002;22:5114–5127
  12. Haunerland NH, Spener F. Fatty acid-binding proteins—insights from genetic manipulations. Prog. Lipid. Res. 2004;43:328–349
  13. Duplus E, Glorian M, Forest C. Fatty acid regulation of gene transcription. J. Biol. Chem. 2000;275:30749–30752
  14. Coe NR, Simpson MA, Bernlohr DA. Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. J. Lipid. Res. 1999;40:967–972
  15. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science. 1996;274:1377–1379
  16. Uysal KT, Scheja L, Wiesbrock SM, Bonner-Weir S, Hotamisligil GS. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology. 2000;141:3388–3396
  17. Scheja L, Makowski L, Uysal KT, Wiesbrock SM, Shimshek DR, Meyers DS, et al. Altered insulin secretion associated with reduced lipolytic efficiency in aP2−/− mice. Diabetes. 1999;48:1987–1994
  18. Baar RA, Dingfelder CS, Smith LA, Bernlohr DA, Wu C, Lange AJ, et al. Investigation of in vivo fatty acid metabolism in AFABP/aP2(−/−) mice. Am. J. Physiol. Endocrinol. Metab. 2005;288:E187–193
  19. Shen WJ, Sridhar K, Bernlohr DA, Kraemer FB. Interaction of rat hormone-sensitive lipase with adipocyte lipid-binding protein. Proc. Natl. Acad. Sci. U.S.A. 1999;96:5528–5532
  20. Jenkins-Kruchten AE, Bennaars-Eiden A, Ross JR, Shen WJ, Kraemer FB, Bernlohr DA. Fatty acid-binding protein–hormone-sensitive lipase interaction. Fatty acid dependence on binding. J. Biol. Chem. 2003;278:47636–47643
  21. Hertzel AV, Smith LA, Berg AH, Cline GW, Shulman GI, Scherer PE, et al. Lipid metabolism and adipokine levels in fatty acid-binding protein null and transgenic mice. Am. J. Physiol. Endocrinol. Metab. 2006;290:E814–823
  22. Maeda K, Uysal KT, Makowski L, Gorgun CZ, Atsumi G, Parker RA, et al. Role of the fatty acid binding protein mal1 in obesity and insulin resistance. Diabetes. 2003;52:300–307
  23. Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, et al. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab. 2005;1:107–119
  24. Boord JB, Fazio S, Linton MF. Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis. Curr. Opin. Lipidol. 2002;13:141–147
  25. Amri EZ, Bertrand B, Ailhaud G, Grimaldi P. Regulation of adipose cell differentiation. I. Fatty acids are inducers of the aP2 gene expression. J. Lipid. Res. 1991;32:1449–1456
  26. Distel RJ, Robinson GS, Spiegelman BM. Fatty acid regulation of gene expression. Transcriptional and post-transcriptional mechanisms. J. Biol. Chem. 1992;267:5937–5941
  27. Melki SA, Abumrad NA. Expression of the adipocyte fatty acid-binding protein in streptozotocin-diabetes: effects of insulin deficiency and supplementation. J. Lipid. Res. 1993;34:1527–1534
  28. Kletzien RF, Foellmi LA, Harris PK, Wyse BM, Clarke SD. Adipocyte fatty acid-binding protein: regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent. Mol. Pharmacol. 1992;42:558–562
  29. Perera RJ, Marcusson EG, Koo S, Kang X, Kim Y, White N, et al. Identification of novel PPARgamma target genes in primary human adipocytes. Gene. 2006;369:90–99
  30. Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, et al. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis. 2007;195:e150–158
  31. Coort SL, Coumans WA, Bonen A, van der Vusse GJ, Glatz JF, Luiken JJ. Divergent effects of rosiglitazone on protein-mediated fatty acid uptake in adipose and in muscle tissues of Zucker rats. J. Lipid. Res. 2005;46:1295–1302
  32. Schachtrup C, Emmler T, Bleck B, Sandqvist A, Spener F. Functional analysis of peroxisome-proliferator-responsive element motifs in genes of fatty acid-binding proteins. Biochem. J. 2004;382:239–245
  33. Park YS, Yoon Y, Ahn HS. Platycodon grandiflorum extract represses up-regulated adipocyte fatty acid binding protein triggered by a high fat feeding in obese rats. World J. Gastroenterol. 2007;13:3493–3499
  34. Lopez IP, Marti A, Milagro FI, Zulet Md Mde L, Moreno-Aliaga MJ, Martinez JA, et al. DNA microarray analysis of genes differentially expressed in diet-induced (cafeteria) obese rats. Obes. Res. 2003;11:188–194
  35. Kushiro M, Takahashi Y, Ide T. Modulation of cutaneous fatty acid-binding protein mRNA expression in rat adipose tissues by hereditary obesity and dietary fats. J. Oleo. Sci. 2007;56:533–541
  36. Gertow K, Pietilainen KH, Yki-Jarvinen H, Kaprio J, Rissanen A, Eriksson P, et al. Expression of fatty-acid-handling proteins in human adipose tissue in relation to obesity and insulin resistance. Diabetologia. 2004;47:1118–1125
  37. Fisher RM, Hoffstedt J, Hotamisligil GS, Thorne A, Ryden M. Effects of obesity and weight loss on the expression of proteins involved in fatty acid metabolism in human adipose tissue. Int. J. Obes. Relat. Metab. Disord. 2002;26:1379–1385
  38. Gertow K, Rosell M, Sjogren P, Eriksson P, Vessby B, de Faire U, et al. Fatty acid handling protein expression in adipose tissue, fatty acid composition of adipose tissue and serum, and markers of insulin resistance. Eur. J. Clin. Nutr. 2006;60:1406–1413
  39. Joosen AM, Bakker AH, Zorenc AH, Kersten S, Schrauwen P, Westerterp KR. PPARgamma activity in subcutaneous abdominal fat tissue and fat mass gain during short-term overfeeding. Int. J. Obes. (Lond.). 2006;30:302–307
  40. Fisher RM, Eriksson P, Hoffstedt J, Hotamisligil GS, Thorne A, Ryden M, et al. Fatty acid binding protein expression in different adipose tissue depots from lean and obese individuals. Diabetologia. 2001;44:1268–1273
  41. Fisher RM, Thorne A, Hamsten A, Arner P. Fatty acid binding protein expression in different human adipose tissue depots in relation to rates of lipolysis and insulin concentration in obese individuals. Mol. Cell. Biochem. 2002;239:95–100
  42. van Beek EA, Bakker AH, Kruyt PM, Hofker MH, Saris WH, Keijer J. Intra- and interindividual variation in gene expression in human adipose tissue. Pflugers Arch. 2007;453:851–861
  43. Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat. Med. 2001;7:699–705
  44. Fu Y, Luo N, Lopes-Virella MF. Oxidized LDL induces the expression of ALBP/aP2 mRNA and protein in human THP-1 macrophages. J. Lipid. Res. 2000;41:2017–2023
  45. Pelton PD, Zhou L, Demarest KT, Burris TP. PPARgamma activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes. Biochem. Biophys. Res. Commun. 1999;261:456–458
  46. Kazemi MR, McDonald CM, Shigenaga JK, Grunfeld C, Feingold KR. Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by toll-like receptor agonists. Arterioscler. Thromb. Vasc. Biol. 2005;25:1220–1224
  47. Llaverias G, Noe V, Penuelas S, Vazquez-Carrera M, Sanchez RM, Laguna JC, et al. Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages. Biochem. Biophys. Res. Commun. 2004;318:265–274
  48. Makowski L, Brittingham KC, Reynolds JM, Suttles J, Hotamisligil GS. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J. Biol. Chem. 2005;280:12888–12895
  49. Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, et al. Combined adipocyte–macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation. 2004;110:1492–1498
  50. Fischer H, Gustafsson T, Sundberg CJ, Norrbom J, Ekman M, Johansson O, et al. Fatty acid binding protein 4 in human skeletal muscle. Biochem. Biophys. Res. Commun. 2006;346:125–130
  51. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin. Chem. 2006;52:405–413
  52. Tso AW, Xu A, Sham PC, Wat NM, Wang Y, Fong CH, et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care. 2007;30:2667–2672
  53. Stejskal D, Karpisek M. Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome?. Eur. J. Clin. Invest. 2006;36:621–625
  54. Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation. 2007;115:1537–1543
  55. Coll B, Cabre A, Alonso-Villaverde C, Lazaro I, Aragones G, Parra S, et al. The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. Atherosclerosis. 2007;
  56. Haider DG, Schindler K, Bohdjalian A, Prager G, Luger A, Wolzt M, et al. Plasma adipocyte and epidermal fatty acid binding protein is reduced after weight loss in obesity. Diabetes Obes. Metab. 2007;9:761–763
  57. Reinehr T, Stoffel-Wagner B, Roth CL. Adipocyte fatty acid-binding protein in obese children before and after weight loss. Metabolism. 2007;56:1735–1741
  58. Yeung DC, Xu A, Cheung CW, Wat NM, Yau MH, Fong CH, et al. Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2007;27:1796–1802
  59. Karpisek M, Stejskal D, Kotolova H, Kollar P, Janoutova G, Ochmanova R, et al. Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia. Eur. J. Clin. Invest. 2007;37:637–642
  60. Tuncman G, Erbay E, Hom X, De Vivo I, Campos H, Rimm EB, et al. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc. Natl. Acad. Sci. U.S.A. 2006;103:6970–6975
  61. Furuhashi M, Tuncman G, Gorgun CZ, Makowski L, Atsumi G, Vaillancourt E, et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature. 2007;447:959–965
  62. Roden M. Blocking fatty acids’ mystery tour: a therapy for metabolic syndrome?. Cell Metab. 2007;6:89–91
  63. Mohlig M, Weickert MO, Ghadamgadai E, Machlitt A, Pfuller B, Arafat AM, et al. Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women. Eur. J. Endocrinol. 2007;157:195–200
  64. Fu Y, Luo N, Lopes-Virella MF, Garvey WT. The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages. Atherosclerosis. 2002;165:259–269

PII: S0168-8227(08)00454-3

doi: 10.1016/j.diabres.2008.09.023

Diabetes Research and Clinical Practice
Volume 82 , Pages S127-S134 , 15 December 2008

Article Tools